From formulation data to clinical evidence
The Pharmacy Hub R&D and Innovation platform can coordinate clinical-development programs through qualified domestic and international research partners.
Beyond analytical and formulation data
This capability can help clients move beyond analytical and formulation data and generate structured clinical evidence designed to better understand:
- Product performance
- Patient response
- Tolerability
- Pharmacokinetics where appropriate
- Comparative performance
- Patient-reported outcomes
- Product usability
- Adherence
- Therapeutic response
- Other protocol-defined clinical endpoints
The development chain
- 01 Formulation science
- 02 Analytical data
- 03 Clinical study
- 04 Evidence
- 05 Scientific dossier
- 06 Commercial / regulatory strategy
One coordinated operational system
Potential services through qualified partners may include:
Strategy & setup
- Study feasibility assessment
- Clinical strategy
- Protocol development
- Country selection
- CRO selection
- Clinical project management
Sites & investigators
- Investigator identification
- Site identification
- Site initiation
Regulatory & ethics
- Regulatory submission coordination
- Ethics committee / IRB coordination
Patients & supply
- Patient recruitment
- Patient screening
- Study drug logistics
- Clinical supply coordination
- Randomization support
Data & monitoring
- Data capture
- Electronic data capture systems
- Monitoring
- Medical monitoring
Safety
- Pharmacovigilance support
- Safety reporting
- Adverse-event reporting
Analysis & reporting
- Biostatistics
- Statistical analysis
- Clinical study report preparation
- Data interpretation
- Scientific publication support
- Dossier preparation
Study types
Depending upon project, applicable laws, ethics approval, and regulatory pathway, programs may include:
Pharmacokinetic studies
Evaluate concentration-time profiles and other protocol-defined PK parameters.
Bioavailability studies
Compare exposure across formulations or delivery systems where scientifically appropriate.
Pilot clinical studies
Generate early evidence regarding feasibility, tolerability, patient response, or product performance.
Proof-of-concept studies
Explore whether a formulation or therapeutic strategy demonstrates clinically meaningful signals that justify additional development.
Comparative studies
Evaluate differences between formulations, dosage forms, dosing strategies, or other protocol-defined interventions.
Patient-experience studies
Evaluate:
- Palatability
- Ease of administration
- Preference
- Adherence
- Product usability
- Patient satisfaction
Real-world evidence programs
Where appropriate, evaluate structured outcomes from actual clinical use.
Observational studies
Generate structured evidence without necessarily assigning an intervention, depending upon protocol and applicable regulations.
Every project should establish
Responsibilities, plans and controls are agreed before a study opens.
Responsibilities
- Sponsor responsibilities
- CRO responsibilities
- Investigator responsibilities
- Quality oversight
Plans & approvals
- Protocol
- Ethics approvals
- Data-management plan
- Monitoring plan
- Statistical analysis plan
Execution & control
- Safety plan
- Clinical supply plan
- Study milestones
- Final reporting requirements
Build claims around data, not marketing alone
For appropriate products and regulatory pathways, clinical-development programs can be designed to generate evidence relevant to scientifically support potential product statements, technical positioning, clinician education, investor materials, or regulatory dossiers.
Potential evidence categories
- Product performance
- Patient preference
- Palatability
- Tolerability
- Pharmacokinetics
- Onset characteristics
- Duration characteristics
- Treatment adherence
- Patient-reported outcomes
- Comparative performance
- Clinical endpoints
No study automatically guarantees that a particular marketing, therapeutic, or regulatory claim can legally be made.
Final claims depend upon:
- Study design
- Statistical outcome
- Evidence quality
- Applicable law
- Product regulatory status
- Intended use
- Promotional regulations
- Appropriate legal and regulatory review
Building a robust scientific evidence package
The clinical-development process should culminate in a structured evidence package. Potential dossier components may include:
- Product description
- Development rationale
- Formulation history
- Analytical data
- Raw-material specifications
- Stability data
- BUD support
- Manufacturing process
- Critical process parameters
- Packaging
- Clinical protocol
- Investigator documentation
- Clinical data
- Statistical analysis
- Safety data
- Clinical study report
- Literature review
- Risk assessment
- Benefit-risk discussion
- Bibliography
- Supporting appendices
The goal is to create an organized body of evidence supporting internal scientific understanding and, where applicable, discussions with:
- Clinicians
- Healthcare organizations
- Commercial partners
- Investors
- Regulatory professionals
- Strategic partners
Generating evidence around real product performance
When clinically and legally appropriate, studies can be designed to investigate defined efficacy or performance endpoints. This may include:
- Objective clinical measurements
- Patient-reported outcomes
- Validated questionnaires
- Treatment response
- Symptom improvement
- Time to effect
- Duration of effect
- Treatment adherence
- Quality-of-life measures
- Tolerability
- Product preference
We help clients design evidence-generation strategies intended to produce meaningful clinical data around clearly defined study endpoints.
Programs can be designed to generate robust evidence capable of supporting scientifically defensible conclusions when study results demonstrate them.
